so we've heard about the increase in frequency and virulence of...

so we've heard about the increase in frequency and virulence of the nrti mutation, m184, caused by rilpivrine in the new Gilead triple pill, Complera...

well the new Gilead 'quad' pill results were just announced at CROI...

http://www.aidsmeds.com/articles/hiv_quad_atripla_1667_22043.shtml

and guess what... more nrti resistance...

the quad results were very similar to the isentress results, compared to the old standard of Atripla...

that is, atripla produced mostly nnrti mutations...

in comparison, the quad (and isentress with truvada) produces integrase resistance with nrti resistance

out of 8 pts with resistance, resistance to tenofovir or emtricitabine occurred in 8 patients in the Quad group, compared with 2 in the Atripla group.

in other words, 4 times more nrti resistance than current = an increasing need for a safe nrti effective against nrti mutations...

know any...

ps this qtr is coming to an end v soon...